Panel to review Celebrex for juvenile RA

An FDA advisory committee will be asked Wednesday to make recommendations about the use of Pfizer's Celebrex celecoxib to treat pain and inflammation associated with juvenile rheumatoid arthritis

Read the full 280 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE